Neuroscience
Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; for the Alzheimer's Disease Neuroimaging Initiative. CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease.J Neurosci., 2010 Feb, 10; 30(6): 2088-2101.
Center for the Study of Human Cognition, Department of Psychology, University of Oslo, NO-0317 Oslo, Norway, Department of Neuropsychology, Ullevaal University Hospital, NO-0407 Oslo, Norway, and Departments of Radiology, Psychiatry, and Neuroscience, University of California, San Diego, La Jolla, California 92093.
Brain atrophy and altered CSF levels of amyloid beta (Abeta(42)) and the microtubule-associated protein tau are potent biomarkers of Alzheimer's disease (AD)-related pathology. However, the relationship between CSF biomarkers and brain morphometry is poorly understood. Thus, we addressed the following questions. (1) Can CSF biomarker levels explain the morphometric differences between normal controls (NC) and patients with mild cognitive impairment (MCI) or AD? (2) How are CSF biomarkers related to atrophy across the brain? (3) How closely are CSF biomarkers and morphometry related to clinical change [clinical dementia rating sum of boxes (CDR-sb)]? Three hundred seventy participants (105 NC, 175 MCI, 90 AD) from the Alzheimer's Disease Neuroimaging Initiative were studied, of whom 309 were followed for 1 year and 176 for 2 years. Analyses were performed across the entire cortical surface, as well as for 30 cortical and subcortical regions of interest. Results showed that CSF biomarker levels could not account for group differences in brain morphometry at baseline but that CSF biomarker levels showed moderate relationships to longitudinal atrophy rates in numerous brain areas, not restricted to medial temporal structures. Baseline morphometry was at least as predictive of atrophy as were CSF biomarkers. Even MCI patients with levels of Abeta(42) comparable with controls and of p-tau lower than controls showed more atrophy than the controls. Morphometry predicted change in CDR-sb better than did CSF biomarkers. These results indicate that morphometric changes in MCI and AD are not secondary to CSF biomarker changes and that the two types of biomarkers yield complementary information.
PMID: 20147537 [PubMed - as supplied by publisher]
- Parkinson's Disease: New Biomarker Effort
From the NIH: NIH launches collaborative effort to find biomarkers for Parkinson's New online resource will support data sharing NIH News 15 January 2013 [snip] "A new initiative aims to accelerate the search for biomarkers — changes in the body...
- Neuropsychology Abstract Of The Day: Cortical Neuroanatomy Of Neuropsychological Deficits
The cortical neuroanatomy of neuropsychological deficits in mild cognitive impairment and Alzheimer's disease: A surface-based morphometric analysis Neuropsychologia. 2011 Oct 15; Ahn HJ, Seo SW, Chin J, Suh MK, Lee BH, Kim ST, Im K, Lee JM, Lee JH,...
- Neuropsychology Abstract Of The Day: Alzheimer's, Mci, & Csf Markers
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M,...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Karas G, Sluimer J, Goekoop R, van der Flier W, Rombouts S, Vrenken H, Scheltens P, Fox N, & Barkhof F. Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. American Journal of Neuroradiology....
- Abstract Of The Day: Structural Mri Markers
den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, & Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Archives of General Psychiatry. 2006 Jan;...
Neuroscience
Neuropsychology Abstract of the Day: Biomakers in Alzheimer's and Mild Cognitive Impairment
Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; for the Alzheimer's Disease Neuroimaging Initiative. CSF Biomarkers in Prediction of Cerebral and Clinical Change in Mild Cognitive Impairment and Alzheimer's Disease.J Neurosci., 2010 Feb, 10; 30(6): 2088-2101.
Center for the Study of Human Cognition, Department of Psychology, University of Oslo, NO-0317 Oslo, Norway, Department of Neuropsychology, Ullevaal University Hospital, NO-0407 Oslo, Norway, and Departments of Radiology, Psychiatry, and Neuroscience, University of California, San Diego, La Jolla, California 92093.
Brain atrophy and altered CSF levels of amyloid beta (Abeta(42)) and the microtubule-associated protein tau are potent biomarkers of Alzheimer's disease (AD)-related pathology. However, the relationship between CSF biomarkers and brain morphometry is poorly understood. Thus, we addressed the following questions. (1) Can CSF biomarker levels explain the morphometric differences between normal controls (NC) and patients with mild cognitive impairment (MCI) or AD? (2) How are CSF biomarkers related to atrophy across the brain? (3) How closely are CSF biomarkers and morphometry related to clinical change [clinical dementia rating sum of boxes (CDR-sb)]? Three hundred seventy participants (105 NC, 175 MCI, 90 AD) from the Alzheimer's Disease Neuroimaging Initiative were studied, of whom 309 were followed for 1 year and 176 for 2 years. Analyses were performed across the entire cortical surface, as well as for 30 cortical and subcortical regions of interest. Results showed that CSF biomarker levels could not account for group differences in brain morphometry at baseline but that CSF biomarker levels showed moderate relationships to longitudinal atrophy rates in numerous brain areas, not restricted to medial temporal structures. Baseline morphometry was at least as predictive of atrophy as were CSF biomarkers. Even MCI patients with levels of Abeta(42) comparable with controls and of p-tau lower than controls showed more atrophy than the controls. Morphometry predicted change in CDR-sb better than did CSF biomarkers. These results indicate that morphometric changes in MCI and AD are not secondary to CSF biomarker changes and that the two types of biomarkers yield complementary information.
PMID: 20147537 [PubMed - as supplied by publisher]
- Parkinson's Disease: New Biomarker Effort
From the NIH: NIH launches collaborative effort to find biomarkers for Parkinson's New online resource will support data sharing NIH News 15 January 2013 [snip] "A new initiative aims to accelerate the search for biomarkers — changes in the body...
- Neuropsychology Abstract Of The Day: Cortical Neuroanatomy Of Neuropsychological Deficits
The cortical neuroanatomy of neuropsychological deficits in mild cognitive impairment and Alzheimer's disease: A surface-based morphometric analysis Neuropsychologia. 2011 Oct 15; Ahn HJ, Seo SW, Chin J, Suh MK, Lee BH, Kim ST, Im K, Lee JM, Lee JH,...
- Neuropsychology Abstract Of The Day: Alzheimer's, Mci, & Csf Markers
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M,...
- Neuropsychology Abstract Of The Day: Mild Cognitive Impairment (mci)
Karas G, Sluimer J, Goekoop R, van der Flier W, Rombouts S, Vrenken H, Scheltens P, Fox N, & Barkhof F. Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. American Journal of Neuroradiology....
- Abstract Of The Day: Structural Mri Markers
den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, & Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Archives of General Psychiatry. 2006 Jan;...